$679 Million is the total value of TCG Crossover Management, LLC's 26 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| COGT | COGENT BIOSCIENCES INC | $54,902,659 | -17.7% | 5,631,042 | 0.0% | 8.08% | -26.1% | |
| KALV | KALVISTA PHARMACEUTICALS, INC | $32,698,617 | +7.0% | 3,395,495 | 0.0% | 4.82% | -3.9% | |
| AVTE | AEROVATE THERAPEUTICS INC | $29,871,288 | -20.9% | 2,201,274 | 0.0% | 4.40% | -28.9% | |
| Icosavax, Inc. | $28,703,706 | -22.0% | 3,703,704 | 0.0% | 4.23% | -29.9% | ||
| VENTYX BIOSCIENCES, INC | $28,330,095 | +5.9% | 815,724 | 0.0% | 4.17% | -4.9% | ||
| TYRA BIOSCIENCES INC | $27,389,948 | -19.1% | 1,989,103 | 0.0% | 4.03% | -27.4% | ||
| SLN | SILENCE THERAPEUTICS PLCadrs | $20,669,873 | +78.5% | 2,104,875 | 0.0% | 3.04% | +60.4% | |
| DYN | DYNE THERAPEUTICS, INC | $14,785,344 | -20.4% | 1,650,150 | 0.0% | 2.18% | -28.5% | |
| KURA | KURA ONCOLOGY INC | $12,983,615 | -13.8% | 1,423,642 | 0.0% | 1.91% | -22.6% | |
| ENTRADA THERAPEUTICS INC | $9,242,289 | +4.4% | 584,955 | 0.0% | 1.36% | -6.3% | ||
| CABA | CABALETTA BIO, INC | $7,409,020 | +17.9% | 486,795 | 0.0% | 1.09% | +5.8% | |
| MRUS | MERUS N.V. | $7,074,000 | -10.4% | 300,000 | 0.0% | 1.04% | -19.5% | |
| CCCC | C4 THERAPEUTICS, INC. | $2,374,427 | -32.4% | 1,276,574 | 0.0% | 0.35% | -39.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
| AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
| TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
| ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
| MERUS N.V. | 8 | Q3 2023 | 3.4% |
| IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
| Geron Corporation | 7 | Q3 2023 | 12.4% |
| ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
| KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
| CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
| Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
| Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
| Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| SC 13G | 2022-08-19 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-18 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.